Cheng AL, Qin S, Ikeda M, Galle PR, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2021 Dec 10. pii: S0168-8278(21)02241.
PMID: 34902530